A

Agenus
D

AGEN

3.33000
USD
-0.12
(-3.34%)
مغلق
حجم التداول
3,446
الربح لكل سهم
-7
العائد الربحي
-
P/E
-0
حجم السوق
78,627,734
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CRVS
    -0.22000
    (-4.99%)
    4.19000 USD
    F
    FATE
    -0.13500
    (-8.74%)
    1.41000 USD
    G
    GNFT
    -0.12000
    (-3.05%)
    3.82000 USD
    O
    ONCY
    -0.00630
    (-0.86%)
    0.72550 USD
    P
    PRTA
    0.270
    (1.77%)
    15.540 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار
المقالات

العنوان: Agenus

القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).